Repurposing of phosphodiesterase-5 inhibitor sildenafil as a therapeutic agent to prevent gastric cancer growth through suppressing c-MYC stability for IL-6 transcription by Zhenzhan Zhang, Wuqing Huang, Donghua Huang, Zhou Xu, Qingfeng Xie, Xin Tan, Wenjun He, Weihao Yang, Guoxin Li, Jianguang Ji, Hao Liu

“…The PDE5 inhibitor sildenafil may serve as a promising adjuvant for GC therapy if further randomized clinical trials confirm its efficacy.…”
Get full text

Plasma Levels of Free Fatty Acids in Women with Gestational Diabetes and Its Intrinsic and Extrinsic Determinants: Systematic Review and Meta-Analysis by Jose Rafael Villafan-Bernal, Mariana Acevedo-Alba, Rodrigo Reyes-Pavon, Guillermo Andres Diaz-Parra, Diana Lucia Lip-Sosa, Hilda Imelda Vazquez-Delfin, Martha Hernandez-Muñoz, Daniel Ely Bravo-Aguirre, Francesc Figueras, Raigam Jafet Martinez-Portilla

Get full text

Tumor aggression-defense index–a novel indicator to predicts recurrence and survival in stage II-III colorectal cancer by Tong Wu, Lin Fang, Yuli Ruan, Mengde Shi, Dan Su, Yue Ma, Ming Ma, Bojun Wang, Yuanyu Liao, Shuling Han, Xiaolin Lu, Chunhui Zhang, Chao Liu, Yanqiao Zhang

“…Subgroup analysis demonstrated potential of TADI in guiding personalized adjuvant therapy for stage II and III CRC. Results Univariate and multivariate Cox analysis indicated that TADI was an independent prognostic indicator. …”
Get full text

Systematic Review and Network Meta-Analysis on Treating Hormone Receptor-Positive Metastatic Breast Cancer After CDK4/6 Inhibitors by Neha Pathak, Abhenil Mittal, Sudhir Kumar, Chitrakshi Nagpal, Eitan Amir, Partha Haldar, Bharath B. Gangadharaiah, Akash Kumar, Ashutosh Mishra, Atul Batra

“…SERDs had worse PFS and OS versus ongoing CDK 4/6i (ribociclib). Conclusion: No therapy emerged as the unequivocal choice in the post-CDK 4/6i domain in unselected subgroups. …”
Get full text

DNA-loaded targeted nanoparticles as a safe platform to produce exogenous proteins in tumor B cells by Maria Cristina Grimaldi, Sara Bozzer, Dick J. Sjöström, Dick J. Sjöström, Linnea I. Andersson, Tom Eirik Mollnes, Tom Eirik Mollnes, Per H. Nilsson, Per H. Nilsson, Luca De Maso, Federico Riccardi, Michele Dal Bo, Daniele Sblattero, Paolo Macor

“…However, the nanoplatform must guarantee both the local production of the protein and the safety of the treatment to allow an effective therapy with reduced systemic toxicity.MethodsIn order to ensure a selective delivery of nucleic acids, we developed poly(lactic-co-glycolic acid) (PLGA)-poly(vinyl alcohol) (PVA) NPs loaded with an Enhanced Green Fluorescent Protein (EGFP)-coding plasmid and covalently coated with antiCD19 recombinant antibody as a targeting mechanism. …”
Get full text

Differential Effects of Angelicin Analogues on NF-κB Activity and IL-8 Gene Expression in Cystic Fibrosis IB3-1 Cells by Ilaria Lampronti, Maria Giulia Manzione, Gianni Sacchetti, Davide Ferrari, Susanna Spisani, Valentino Bezzerri, Alessia Finotti, Monica Borgatti, Maria Cristina Dechecchi, Giorgia Miolo, Giovanni Marzaro, Giulio Cabrini, Roberto Gambari, Adriana Chilin

“…Other analogues displayed higher activities; in particular, the most interesting compounds showing relevant anti-inflammatory effects were found to cause 56–83% reduction of IL-8 mRNA expression at low concentrations (1–10 μM), without changes in cell proliferation pattern, demonstrating their potential interest for a possible development of anti-inflammatory therapy of cystic fibrosis.…”
Get full text

Thyroid Hormone Activation Regulates the Crosstalk between Breast Cancer and Mesenchymal Stem Cells by Annarita Nappi, Vittoria D’Esposito, Caterina Miro, Alessia Parascandolo, Annunziata Gaetana Cicatiello, Serena Sagliocchi, Lucia Acampora, Sepehr Torabinejad, Federica Restolfer, Maddalena Raia, Melania Murolo, Emery Di Cicco, Pietro Formisano, Monica Dentice

“…Conclusions: Thus, we argue that intracellular activation of THs via D2 is a critical requirement for invasive and metastatic conversion of breast cancer cells, advising the blocking of D2 as a potential therapeutic tool for cancer therapy.…”
Get full text

Effect of Cardiac Exercise Rehabilitation on Epicardial Adipose Tissue Thickness in Patients with Coronary Heart Disease by Xing XING, Xinying GE, Ao GENG, Hongyan JIANG

“…The patients in the exercise rehabilitation group, on the basis of the conventional secondary preventive drug therapy for CHD, conducted cardiac exercise rehabilitation for 12 weeks. …”
Get full text

The effects of Thymus capitatus essential oil topical application on milk quality: a systems biology approach by Ralph Nehme, Chiara Gini, Elise Vanbergue, Sergine Even, Filippo Biscarini, Sonia Andrés, Lucie Rault, Faustine Noel, Valerie Hardit, Said Bouhallab, David M. Pereira, Riadh Ksouri, Philippe Roussel, Secundino López, Paola Cremonesi, Bianca Castiglioni, Donatella Caruso, Fiorenza Faré, Manuela Fontana, Fabrizio Ceciliani, Latifa Abdennebi-Najar

“…More studies should be conducted to ensure the safe use of TCEO in dairy cows and explore its potential benefits on antibiotic-resistant bacteria as an alternative or support for antibiotic therapy.…”
Get full text

Anti-TROVE2 Antibody Determined by Immune-Related Array May Serve as a Predictive Marker for Adalimumab Immunogenicity and Effectiveness in RA by Po-Ku Chen, Joung-Liang Lan, Yi-Ming Chen, Hsin-Hua Chen, Shih-Hsin Chang, Chia-Min Chung, Nurul H. Rutt, Ti-Myen Tan, Raja Nurashirin Raja Mamat, Nur Diana Anuar, Jonathan M. Blackburn, Der-Yuan Chen

“…In Cohort-1, 24 plasma samples (6 ADAb-positive and 6 ADAb-negative patients at baseline and week 24 of adalimumab therapy, respectively) were assayed with immune-related microarray containing 1,636 correctly folded functional proteins. …”
Get full text

Bacterial flora of the eyelids and conjunctiva in the development of inflammatory pathology in the anterior part of the eye by E.A. Kleshcheva, G.M. Chernakova, N.V. Melnikova, A.E. Kleshchev

“…In conclusion, the article underscores the potential of netilmicin as a valuable option for empirical therapy in ocular infections. Its efficacy, safety, and broad-spectrum activity make it well-suited for cases wh ere a powerful and non-toxic antibiotic is required. …”
Get full text

Clinical efficacy and hemodynamic effects of levosimendan in cardiac surgery patients after surgery by Meiling Zhao, Yunfeng Hou, Meng Yuan, Shuang Ma, Yifeng Yue

“…The hemodynamic states of the two groups were compared both before and after therapy. 48 h after surgery, echocardiography was performed in both groups to determine cardiac function. 48 h after surgery, N-terminal pro-brain B-type natriuretic peptide (NT-Pro-BNP) levels were compared between the two groups. …”
Get full text

A perspective from the National Eye Institute Extracellular Vesicle Workshop: Gaps, needs, and opportunities for studies of extracellular vesicles in vision research by Sun Young Lee, Mikael Klingeborn, Jeff W. M. Bulte, Daniel T. Chiu, Michael Chopp, Christopher W. Cutler, Saumya Das, Charles E. Egwuagu, Christie D. Fowler, Sarah F. Hamm‐Alvarez, Hakho Lee, Yutao Liu, Ben Mead, Tara L. Moore, Sriram Ravindran, Ashok K. Shetty, Johan Skog, Kenneth W. Witwer, Ali R. Djalilian, Alissa M. Weaver

“…The workshop aimed to review current knowledge in EV research and explore gaps, needs and opportunities for EV research in the eye, including EV biology and applications of EVs in diagnosis, therapy and prognosis within the visual system. This perspective encapsulates the workshop's deliberations, highlighting the current landscape and potential implications of EV research in advancing eye health and addressing visual diseases.…”
Get full text

CLINICAL CARE PATHWAY AND MANAGEMENT OF MAJOR BLEEDING ASSOCIATED WITH NON-VITAMIN K ANTAGONIST ORAL ANTICOAGULANTS: A MODIFIED DELPHI CONSENSUS FROM SAUDI ARABIA AND UAE by Abdulrahman Al Raizah, Fakhr Alayoubi, Galal Hassan Abdelnaby, Hazzaa Alzahrani, Majid Farraj Bakheet, Mohammed A Alskaini, Rasha Buhumaid, Sameer Al Awadhi, Sara Nooruddin Kazim, Thiagarajan Jaiganesh, Zohair Al Asiri

“… Background: The non-vitamin K antagonist oral anticoagulants (NOACs) have become the mainstay anticoagulation therapy for patients requiring oral anticoagulants (OACs) in the Gulf Council Cooperation (GCC) countries. …”
Get full text

The regulatory role of cystatin C in autophagy and neurodegeneration by T. A. Korolenko, A. B. Shintyapina, A. B. Pupyshev, A. A. Akopyan, G. S. Russkikh, M. A. Dikovskaya, V. A. Vavilin, E. L Zavjalov, M. A. Tikhonova, T. G. Amstislavskaya

“…Controlled expression of a cystatin C peptide has been proposed as a new approach to therapy for Alzheimer’s disease. In Parkinson’s disease, serum cystatin C levels can predict disease severity and cognitive dysfunction, although the exact involvement of cystatin C remains unclear. …”
Get full text

Diagnostic disparities in inborn errors of immunity: From clinical suspicion to diagnosis by Karen M. Gilbert, PhD, Robert F. LeCates, MA, Alison A. Galbraith, MD, MPH, Paul J. Maglione, MD, PhD, Stephanie Argetsinger, MPH, Nicholas L. Rider, DO, Jocelyn R. Farmer, MD, PhD, Mei-Sing Ong, PhD

“…Longer diagnostic interval was associated with a longer interval to receiving IgR therapy (hazard ratio, 0.64; 95% confidence interval, 0.49-0.83). …”
Get full text

Establishment and application of a rapid new detection method for antimicrobial susceptibility testing of Klebsiella pneumoniae based on MALDI-TOF MS by Yapei Zhang, Fanghua Fan, Xuan Wang, Jie Zhu, Shilei Dong

“…Guidelines recommend targeted therapy based on minimum inhibitory concentration results, which directly reflect the effectiveness of antibacterial drugs. …”
Get full text

Non-lytic spread of poliovirus requires the nonstructural protein 3CD by David Aponte-Diaz, Jayden M. Harris, Tongjia Ella Kang, Victoria Korboukh, Mohamad S. Sotoudegan, Jennifer L. Gray, Neela H. Yennawar, Ibrahim M. Moustafa, Andrew Macadam, Craig E. Cameron

“…This discovery should facilitate the identification of the specific steps of the cellular secretory autophagy pathway and corresponding factors commandeered by the virus and may uncover novel targets for antiviral therapy.…”
Get full text

Afatinib and Necitumumab in EGFR-Mutant NSCLC with Acquired Resistance to Tyrosine Kinase Inhibitors by Nathaniel J. Myall, MD, Jennifer G. Whisenant, PhD, Joel W. Neal, MD, PhD, Wade T. Iams, MD, Karen L. Reckamp, MD, Sally York, MD, PhD, Lynne D. Berry, PhD, Yu Shyr, PhD, Leora Horn, MD, Heather A. Wakelee, MD, Sukhmani K. Padda, MD

“…Preclinical studies suggest that combining EGFR TKI and monoclonal antibody therapies may have activity in EGFR-mutated NSCLC that has progressed on TKI therapy alone. …”
Get full text

Dihydrotanshinone I enhanced BRAF mutant melanoma treatment efficacy by inhibiting the STAT3/SOX2 signaling pathway by Xing Luo, Yi Duan, Jinwei He, CongGai Huang, Jun Liu, Yifan Liu, Mengdei Xu, Qiong Dai, Zhihui Yang

“…Finally, we proved that the combined therapy of DHT and BRAF/MEK inhibitors is reliable and effective at animal and cell levels.ConclusionIn BRAF mutant melanoma cells, DHT suppresses the STAT3/SOX2 signaling pathway. …”
Get full text